Spinal cord cell transplant aims to slow ALS
NCT ID NCT02478450
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial investigates whether injecting Q-Cells—specialized human cells that support nerve function—into the spinal cord is safe for people with ALS. Up to 30 participants receive injections in the lower or upper spinal cord, with some receiving higher doses. Researchers monitor side effects and measure changes in muscle strength, breathing, and daily function to see if the treatment might slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Q-Cells (human glial restricted progenitor cells)
- What this could lead to
- If safe and effective, this cell therapy could slow or stabilize ALS progression by replacing damaged support cells in the spinal cord.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. Risks include side effects from the injection procedure or the cells themselves.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Can filtering the blood slow ALS in patients with a rogue antibody?
- Custom-Made genetic drug takes aim at rare form of ALS
- Tailored genetic drug takes aim at a rare form of ALS
- Custom-Made genetic drug takes aim at rare form of ALS
- App aims to give a voice to those with speech difficulties